Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Chest
; 158(1): e15-e19, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: covidwho-213323
ABSTRACT
Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China. Since then, COVID-19 has become a pandemic affecting more than 4.1 million people worldwide. Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH). Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking. We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab. Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS. These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Infecciones por Coronavirus
/
Linfohistiocitosis Hemofagocítica
/
Pandemias
/
Anticuerpos Monoclonales Humanizados
/
Síndrome de Liberación de Citoquinas
Tipo de estudio:
Reporte de caso
/
Estudios diagnósticos
/
Estudio pronóstico
Tópicos:
Covid persistente
Idioma:
Inglés
Revista:
Chest
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS